NCT06625814View on ClinicalTrials.gov

A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

August 19, 2024

Study Completion Date

September 11, 2024

Conditions
Healthy
Interventions
DRUG

Levothyroxine

single oral dose

DRUG

Enlicitide Decanoate

single oral dose

Trial Locations (1)

68502

Celerion (Site 0001), Lincoln

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06625814 - A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028) | Biotech Hunter | Biotech Hunter